Correlation Between Unicycive Therapeutics and Precision BioSciences

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Unicycive Therapeutics and Precision BioSciences at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Unicycive Therapeutics and Precision BioSciences into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Unicycive Therapeutics and Precision BioSciences, you can compare the effects of market volatilities on Unicycive Therapeutics and Precision BioSciences and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Unicycive Therapeutics with a short position of Precision BioSciences. Check out your portfolio center. Please also check ongoing floating volatility patterns of Unicycive Therapeutics and Precision BioSciences.

Diversification Opportunities for Unicycive Therapeutics and Precision BioSciences

-0.85
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Unicycive and Precision is -0.85. Overlapping area represents the amount of risk that can be diversified away by holding Unicycive Therapeutics and Precision BioSciences in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Precision BioSciences and Unicycive Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Unicycive Therapeutics are associated (or correlated) with Precision BioSciences. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Precision BioSciences has no effect on the direction of Unicycive Therapeutics i.e., Unicycive Therapeutics and Precision BioSciences go up and down completely randomly.

Pair Corralation between Unicycive Therapeutics and Precision BioSciences

Given the investment horizon of 90 days Unicycive Therapeutics is expected to generate 2.01 times more return on investment than Precision BioSciences. However, Unicycive Therapeutics is 2.01 times more volatile than Precision BioSciences. It trades about 0.04 of its potential returns per unit of risk. Precision BioSciences is currently generating about -0.04 per unit of risk. If you would invest  73.00  in Unicycive Therapeutics on September 12, 2024 and sell it today you would earn a total of  5.10  from holding Unicycive Therapeutics or generate 6.99% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Unicycive Therapeutics  vs.  Precision BioSciences

 Performance 
       Timeline  
Unicycive Therapeutics 

Risk-Adjusted Performance

17 of 100

 
Weak
 
Strong
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Unicycive Therapeutics are ranked lower than 17 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak fundamental indicators, Unicycive Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.
Precision BioSciences 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Precision BioSciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's forward indicators remain quite persistent which may send shares a bit higher in January 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.

Unicycive Therapeutics and Precision BioSciences Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Unicycive Therapeutics and Precision BioSciences

The main advantage of trading using opposite Unicycive Therapeutics and Precision BioSciences positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Unicycive Therapeutics position performs unexpectedly, Precision BioSciences can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Precision BioSciences will offset losses from the drop in Precision BioSciences' long position.
The idea behind Unicycive Therapeutics and Precision BioSciences pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Other Complementary Tools

Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency